Clinical Research Directory

Inclusion Criteria: 1. Within the first year to 3 years after the first stroke; 2. Unilateral infarction located in the territory of the middle cerebral artery, but not involving the cerebellum, thalamus, and brainstem; 3. Aged 18-80 years; 4. TMS standard: TMS induces muscle evoked potential (MEP). In the contracted state of the paralyzed muscle (maximum voluntary contraction of 20-50%), a reliable standard MEP (in 5/10 trials with 50-100uv) can be induced; 5. Researchers determine the medical and neurological condition of the participant to be stable based on the participant's medical history, physical examination, and neurological examination; 6. Moderate-severe unilateral upper limb paralysis, i.e., the Fugl-Meyer Assessment (FMA-UE) scale score is ≤47; 7. The distal extremity of the limb has some degree of motor function (flexion of the elbow joint or extension of the elbow joint or partial finger flexion with FMA-UE ≥1); 8. mRS\<4 points, able to cooperate with assessment and rehabilitation; 9. No spasticity or mild spasticity in any part of the affected limb (intramuscular rotator muscle and adductor muscle of the shoulder joint, flexor muscle of the elbow joint, flexor muscle of the wrist joint or finger flexor muscle), modified Ashworth scale (MAS) \<4 points; 10. MMSE\>24 points. Exclusion Criteria: 1. Primary hemorrhagic stroke or severe hemorrhagic conversion; 2. Any progressive neurological or somatic disease that impairs the function of the affected limb other than stroke; 3. Moderate to severe neglect or disinhibition of the affected limb; 4. Any other neurological disorder that may compromise study safety, including central nervous system vasculitis, intracranial tumors, intracranial aneurysms, multiple sclerosis, or arteriovenous malformations; 5. Pain intensity on the affected limb NRS ≥5 or severe sensory disturbance, NIHSS (item 8) = 2; 6. Exclusion of cardioembolic stroke, patients requiring long-term anticoagulation; 7. Unable to stop anticoagulation treatment at least 10 days prior to surgery (i.e., antiplatelet and/or anticoagulant therapy); 8. Seizure(s) after stroke or potential risk of seizure(s); 9. Switching to oral spasticity medication within 2 weeks of enrollment, or injection of botulinum toxin in the affected arm within 4 months, and/or intention to start taking spasticity medication or inject botulinum toxin during the study follow-up period or within 12 months after implantation; 10. The presence of active psychosis that may affect treatment effect, such as psychosis or severe personality disorder; 11. Untreated or inadequately treated depression, i.e., Beck Depression Inventory score of 20 or more at admission; 12. Diagnosis of dementia; 13. Uncontrolled hypertension or history of cardiovascular disease for a long time; 14. MRI contraindications, such as implanted metal devices or electronic devices (pacemakers, defibrillators, spinal cord stimulators); 15. Participated in another device, biological, or drug study within 30 days of consenting to participate in the current study; 16. Non-pregnant or fertile women must use acceptable contraception, and pregnant women are excluded or terminated from the study; 17. Received decompressive craniectomy; 18. The patient has severe cerebral small vessel disease, basilar artery vascular disease, and/or any other structural abnormalities of the cerebellum, cerebellar peduncles, and brainstem that prevent safe placement of DBS; 19. The investigator determines that the patient has a condition that would significantly increase the risk of study non-compliance, study safety, and/or study integrity. For the safety of the subject, for example, if the subject experiences an exacerbation of their condition, a serious adverse event, or poor compliance.